SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,296,425 | -30.2% | 47,023 | -23.9% | 0.00% | -100.0% |
| Q2 2023 | $1,857,527 | -0.9% | 61,794 | +19.5% | 0.00% | 0.0% |
| Q1 2023 | $1,873,924 | +26.2% | 51,723 | +24.2% | 0.00% | – |
| Q4 2022 | $1,485,049 | -11.3% | 41,633 | -15.8% | 0.00% | -100.0% |
| Q3 2022 | $1,674,000 | +8.7% | 49,458 | -7.1% | 0.00% | – |
| Q2 2022 | $1,540,000 | -55.2% | 53,264 | -50.0% | 0.00% | -100.0% |
| Q1 2022 | $3,440,000 | -0.7% | 106,438 | -10.4% | 0.00% | 0.0% |
| Q4 2021 | $3,463,000 | -8.8% | 118,766 | -16.6% | 0.00% | 0.0% |
| Q3 2021 | $3,798,000 | -1.4% | 142,407 | +13.8% | 0.00% | 0.0% |
| Q2 2021 | $3,852,000 | -30.7% | 125,111 | -41.0% | 0.00% | 0.0% |
| Q1 2021 | $5,555,000 | +65.6% | 212,176 | +59.1% | 0.00% | 0.0% |
| Q4 2020 | $3,354,000 | +14.4% | 133,319 | -5.2% | 0.00% | 0.0% |
| Q3 2020 | $2,931,000 | -4.1% | 140,567 | +9.3% | 0.00% | 0.0% |
| Q2 2020 | $3,055,000 | +42.7% | 128,651 | +8.1% | 0.00% | 0.0% |
| Q1 2020 | $2,141,000 | -43.1% | 119,029 | -25.0% | 0.00% | 0.0% |
| Q4 2019 | $3,766,000 | -33.7% | 158,754 | -23.2% | 0.00% | -50.0% |
| Q3 2019 | $5,680,000 | -38.2% | 206,651 | -25.7% | 0.00% | -33.3% |
| Q2 2019 | $9,198,000 | -29.1% | 277,977 | -24.9% | 0.00% | -25.0% |
| Q1 2019 | $12,966,000 | -36.1% | 370,010 | -39.4% | 0.00% | -42.9% |
| Q4 2018 | $20,286,000 | -49.2% | 610,635 | -23.1% | 0.01% | -36.4% |
| Q3 2018 | $39,962,000 | -30.2% | 793,683 | -17.1% | 0.01% | -35.3% |
| Q2 2018 | $57,290,000 | +39.6% | 957,210 | +6.8% | 0.02% | +41.7% |
| Q1 2018 | $41,041,000 | +36.3% | 896,110 | +18.6% | 0.01% | +33.3% |
| Q4 2017 | $30,105,000 | +22.3% | 755,422 | +22.7% | 0.01% | +12.5% |
| Q3 2017 | $24,624,000 | -13.6% | 615,584 | -6.9% | 0.01% | -11.1% |
| Q2 2017 | $28,501,000 | +77.5% | 661,275 | +28.9% | 0.01% | +80.0% |
| Q1 2017 | $16,057,000 | +25.0% | 513,009 | +0.8% | 0.01% | 0.0% |
| Q4 2016 | $12,847,000 | +9.6% | 508,768 | +7.3% | 0.01% | +25.0% |
| Q3 2016 | $11,724,000 | +6.8% | 474,076 | -12.1% | 0.00% | 0.0% |
| Q2 2016 | $10,982,000 | +29.1% | 539,104 | -3.4% | 0.00% | +33.3% |
| Q1 2016 | $8,507,000 | +22.5% | 557,834 | +7.9% | 0.00% | 0.0% |
| Q4 2015 | $6,945,000 | +7.7% | 516,784 | +12.5% | 0.00% | 0.0% |
| Q3 2015 | $6,447,000 | -20.5% | 459,426 | -3.9% | 0.00% | 0.0% |
| Q2 2015 | $8,114,000 | -7.2% | 477,842 | -33.9% | 0.00% | +50.0% |
| Q1 2015 | $8,740,000 | +231.4% | 722,628 | +127.4% | 0.00% | +100.0% |
| Q4 2014 | $2,637,000 | +21875.0% | 317,726 | +23487.7% | 0.00% | – |
| Q3 2014 | $12,000 | -55.6% | 1,347 | -46.0% | 0.00% | – |
| Q2 2014 | $27,000 | – | 2,494 | +7945.2% | 0.00% | – |
| Q4 2013 | $0 | – | 31 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |